Trial reportThe Journal of allergy and clinical immunology2017
Omalizumab facilitates rapid oral desensitization for peanut allergy.
Trial report in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 6 syntheses or guidelines pooled it, 317 citations in OpenAlex.
- Eosinophilic Esophagitis following Oral Immunotherapy: A Systematic Review and Meta-Analysis.International archives of allergy and immunology · 2026Pooled it
- Pooled it
- Biologic-assisted immunotherapy for pediatric food allergy: a systematic review.Frontiers in allergy · 2026Pooled it
- Systematic review and meta-analysis of omalizumab for IgE-mediated food allergy in children and young adults.Frontiers in immunology · 2025Pooled it
- Positive rate of wheat allergens in the Chinese allergic population: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Adverse events associated with peanut oral immunotherapy in children - a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Understanding the Variability of Peanut-Oral Immunotherapy Responses by Multi-Omics Profiling of Immune Cells.Allergy · 2025Trial
- Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.Allergy · 2025Trial
- Omalizumab for the Treatment of Multiple Food Allergies.The New England journal of medicine · 2024Trial
- Double-Blind, Placebo-Controlled Study of E-B-FAHF-2 in Combination With Omalizumab-Facilitated Multiallergen Oral Immunotherapy.The journal of allergy and clinical immunology. In practice · 2023Trial
- High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy.Cell reports. Medicine · 2021Trial
- Immunoglobulin E blockade during food allergen ingestion enhances the induction of inhibitory immunoglobulin G antibodies.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2019Trial
- Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.The lancet. Gastroenterology & hepatology · 2018Trial
- Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab.The journal of allergy and clinical immunology. In practiceTrial
- Indications for Biological Treatment Combined with Allergen-Specific Immunotherapy: Who Is It Really Intended for?Journal of clinical medicine · 2026Review
- Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Review
- Article
- From anaphylaxis to eosinophilic esophagitis during omalizumab treatment in a boy with severe asthma and food allergy: a case report.Frontiers in immunology · 2026Article
- Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.Journal of inflammation research · 2026Review
- Comparative Efficacy of Combined and Standalone Oral Immunotherapies for Peanut Allergy: a Bayesian Network Meta-Analysis of RCTs.Clinical reviews in allergy & immunology · 2025Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPeanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions.
objectiveWe sought to evaluate whether omalizumab facilitated rapid peanut desensitization in highly allergic patients.
methodsThirty-seven subjects were randomized to omalizumab (n = 29) or placebo (n = 8). After 12 weeks of treatment, subjects underwent a rapid 1-day desensitization of up to 250 mg of peanut protein, followed by weekly increases up to 2000 mg. Omalizumab was then discontinued, and subjects continued on 2000 mg of peanut protein. Subjects underwent an open challenge to 4000 mg of peanut protein 12 weeks after stopping study drug. If tolerated, subjects continued on 4000 mg of peanut protein daily.
resultsThe median peanut dose tolerated on the initial desensitization day was 250 mg for omalizumab-treated subjects versus 22.5 mg for placebo-treated subject. Subsequently, 23 (79%) of 29 subjects randomized to omalizumab tolerated 2000 mg of peanut protein 6 weeks after stopping omalizumab versus 1 (12%) of 8 receiving placebo (P < .01). Twenty-three subjects receiving omalizumab versus 1 subject receiving placebo passed the 4000-mg food challenge. Overall reaction rates were not significantly lower in omalizumab-treated versus placebo-treated subjects (odds ratio, 0.57; P = .15), although omalizumab-treated subjects were exposed to much higher peanut doses.
conclusionOmalizumab allows subjects with peanut allergy to be rapidly desensitized over as little as 8 weeks of peanut oral immunotherapy. In the majority of subjects, this desensitization is sustained after omalizumab is discontinued. Additional studies will help clarify which patients would benefit most from this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.